Journal of Traditional Medicine & Clinical Naturopathy
Open Access

Research Article

Evaluation of Patients Receiving Jeeva^® at an Integrative Pulmonary Care Center

Narinder Singh Parhar^1*, Gloria St John¹, Ajaipal Singh Gill¹, Frank Son¹ and Sachin A Shah^1,2

¹Parhar Health Systems, Roseville, California, USA

²Pharmacy Practice, Thomas J long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, California, USA

Corresponding Author:

Narinder Singh Parhar
Sutter Independent Physician 584 N, Sunrise Avenue, #100, Roseville, California
Tel: (916) 773-2990
Fax: (916) 773-5154
E-mail: Parharmd@gmail.com

Received Date: October 17, 2016; Accepted Date: October 25, 2016; Published Date: October 31, 2016

Citation: Parhar NS, John GS, Gill AS, Son F, Shah SA (2016) Evaluation of Patients Receiving Jeeva^® at an Integrative Pulmonary Care Center. J Tradi Med Clin Natur 5:195.

Copyright: © 2016 Parhar NS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction: Asthma and COPD contribute significantly to morbidity, mortality, and social-economic burden. Integrative Pulmonary Care center (IPCC) is a specialized program that has an integrative approach to respiratory care. Notably, eligible patients may receive a novel plant based therapeutic option (Jeeva®) in addition to standard of care. Jeeva® integrates several nutraceuticals known to have immune-modulatory, anti-inflammatory andantioxidantproperties. Methods: An evaluation of patient records was performed for all asthma/COPD patients enrolled in the IPCC program who had consented to consume Jeeva®. Demographic data, past medical history, and spirometry data (FEV1, FVC, FEV1/FVC, FEV1% predicted, FVC% predicted, FEV1/FVC% predicted) were collected along with a survey-based assessment of quality-of-life. The primary endpoint was the maximum change in FEV1 and FVC pre-bronchodilator after Jeeva® initiation. A paired students’ t-test was utilized to compare the maximum change post- Jeeva® from baseline. Intent-to-treat analysis was performed using the last-observation carried forward methodology. Results: A total of 26 patients were included for analyses. Median duration of Jeeva® consumption was approximately 6 months (range 1–12 months). There was a statistically significant change in FEV1 and FVC from baseline [1.64 ± 0.72 L to 1.80 ± 0.72 L; (p=0.019) and 2.26 ± 0.80L to 2.50 ± 0.74 L (p=0.004) respectively]. Quality-oflife improved statistically significantly and there was a notable decrease in medication burden. Conclusion: Patients receiving Jeeva® as part of the IPCC significantly improved pre-bronchodilator FEV1 and FVC from baseline. A small improvement in quality-of-life and medication burden was evident. Further studies looking at Jeeva® in a randomized, placebo-controlled, clinical-trial is warranted.

Keywords